MedTrace Logo

A Study for Adults With Plaque Psoriasis

NCT01018810 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2011-07-29

Study results available
· View outcomes & findings →

Summary

In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.

Conditions

Interventions

DRUG

LY2525623 Intravenous

administered intravenously at randomization and every 2 weeks for 6 weeks

DRUG

LY2525623 Subcutaneous

administered subcutaneously at randomization and every 2 weeks for 6 weeks

DRUG

Placebo Intravenous

administered intravenously at randomization and every 2 weeks for 6 weeks

DRUG

Placebo Subcutaneous

administered subcutaneously at randomization and every 2 weeks for 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-05-31
Completion
2010-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018810 on ClinicalTrials.gov